Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis (Q27692023)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis	scientific article

Statements

scholarly article

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis (English)

1 reference

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Yuya Mizuno

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Takefumi Suzuki

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kazunari Yoshida

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Masaru Mimura

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Walter Wolfgang Fleischhacker

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Hiroyuki Uchida

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

0 references

publication date

November 2014

1 reference

Schizophrenia Bulletin

1 reference

40

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1385-1403

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

6

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Interventions to reduce weight gain in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

20 March 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

20 March 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

20 March 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

20 March 2017

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

20 March 2017

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

20 March 2017

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Medical comorbidity in women and men with schizophrenia: a population-based controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Nizatidine for the treatment of patients with quetiapine-induced weight gain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

29 September 2017

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

2 June 2018

Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

2 June 2018

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

2 June 2018

Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

2 June 2018

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

2 June 2018

Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Amantadine for weight gain associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Obesity among individuals with serious mental illness

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin

1 reference

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBU030

21 January 2018

Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

27 November 2018

A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

27 November 2018

Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

27 November 2018

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

27 November 2018

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193713

27 November 2018

Sibutramine (Meridia) withdrawn

1 reference

https://pubmed.ncbi.nlm.nih.gov/24636967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Body mass index in persons with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24636967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FAILURE OF DEXTROAMPHETAMINE SULFATE TO INFLUENCE EATING AND SLEEPING PATTERNS IN OBESE SCHIZOPHRENIC PATIENTS: CLINICAL AND PHARMACOLOGICAL SIGNIFICANCE

1 reference

https://pubmed.ncbi.nlm.nih.gov/24636967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pro12Ala polymorphism of the PPAR-γ2 gene, metabolic syndrome and response to metformin in clozapine-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24636967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/SCHBUL/SBU030

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24636967%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27692023&oldid=1970154715"